Shares in Synektik on the Warsaw Stock Exchange now cost 150% more than at the beginning of 2023, the Parkiet website reported on Tuesday.
The Polish firm, which also produces radiopharmaceuticals, has boosted sales of its medical systems and services over the past several quarters, leading to a jump in financial results, according to officials.
This is largely down to "the growth of the market in surgical robotics," with some surgical treatments growing by 100% compared with the previous year, said Synektik's founder and CEO Cezary Kozanecki.
In the first quarter of the 2023/24 financial year, Synektik's sales of medical equipment totalled PLN 157 million (EUR 35.8 million), up from PLN 90.8 million (EUR 20.7 million) the year before, Parkiet reported.
In the current year, Synektik "is likely to continue to secure high levels of sales of robotic systems, as well as of services to do with the implementation and maintenance of these systems," notably in treatments using the Da Vinci surgical method, according to Katarzyna Kosiorek from Trigon, a stockbroking firm.
Source: Parkiet, StockWatch.pl